Plasma Methylated DNA Markers for Melanoma Surveillance-Reference-Cited by-同舟云学术

Plasma Methylated DNA Markers for Melanoma Surveillance

Published:2023-09 Issue:7 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Berger Calise K.¹^ORCID,Taylor William R.¹,Mahoney Douglas W.²^ORCID,Burger Kelli N.²,Doering Karen A.¹^ORCID,Gonser Anna M.¹,Cao Xiaoming¹,Heilberger Justin³,Gysbers Brianna J.¹^ORCID,Foote Patrick H.¹,Kottschade Lisa A.⁴^ORCID,Markovic Svetomir N.⁴,Lehman Julia S.⁵⁶^ORCID,Katerov Viatcheslav E.³^ORCID,Allawi Hatim T.³,Kisiel John B.¹,Meves Alexander⁶^ORCID

Affiliation:

1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN

2. Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN

3. Exact Sciences Development Company, LLC, Madison, WI

4. Department of Oncology, Mayo Clinic, Rochester, MN

5. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

6. Department of Dermatology, Mayo Clinic, Rochester, MN

Abstract

Plasma-based MDMs may offer a cost-effective alternative to imaging for melanoma detection. Early results show 80% sensitivity and 100% specificity against cancer-free controls. Further study needed. #MelanomaResearch #EarlyDetection

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.23.00389

Reference24 articles.

1. Epidemiology of Melanoma

2. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9

3. Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation

4. Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma

5. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility